bendamustine / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

92 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bendamustine / Generic mfg.
2011-000796-14: COSMIC: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL

Ongoing
2
82
Europe
Ofatumumab, Fludarabine, Cyclophosphamide, Cyclophosphamide Injection, Bendamustine, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Coated tablet, Powder for solution for injection, Powder for concentrate for solution for infusion, Arzerra (Ofatumumab), Cyclophosphamide Injection
Leeds Teaching Hospitals NHS Trust, GlaxoSmithKline
Chronic Lymphocytic Leukaemia (CLL), Leukaemia is a cancer of the white blood cells. CLL is the most common type of Leukaemia. People with CLL make too many white blood cells called lymphocytes., Diseases [C] - Cancer [C04]
 
 
2011-002307-14: Phase II salvage treatment with Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL). Traitement de phase II par Bendamustine, Ofatumumab et MethylPrednisolone (BOMP) dans les leucémies lymphoïdes chroniques B (LLC-B) en rechute.

Ongoing
2
115
Europe
LEVACT 2,5 mg/ml powder for infusion, Ofatumumab, GSK 1841157, Powder for infusion, Concentrate and solvent for solution for infusion, Chlorhydrate de bendamustine, Arzerra ®
Groupe Est Ouest des Leucémies et Autres Maladies du Sang, Groupe Est Ouest des Leucémies et Autres Maladies du Sang
relapsed B-cell chronic lymphocytic leukemia (B-CLL). LLC B, relapsed B-cell chronic lymphocytic leukemia (B-CLL). leucémies lymphoïdes chroniques B (LLC-B) en rechute, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-005338-13: Treatment with Ofatumumab and Bendamustine in patients with lymphoma resistant to previous therapies Trattamento con Ofatumumab e Bendamustina in pazienti con linfoma resistente alle precedenti terapie

Ongoing
2
73
Europe
Bendamustine, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Arzerra
Istituto Clinico Humanitas - Humanitas Cancer Center, Regione Lombardia, GlaxoSmithKline
Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory Linfomi non Hodgkin indolenti follicolari e non follicolari, recidivati/refrattari, Indolent Lymphoma Linfomi indolenti, Diseases [C] - Cancer [C04]
 
 
2014-000130-37: Clinical trial to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who did not responded after previous high-dose therapy STUDIO CLINICO PER VALUTARE L'EFFICACIA E LA SICUREZZA DELL'ASSOCIAZIONE DI BENDAMUSTINA-MELFALAN COME REGIME PREPARATORIO AL TRAPIANTO AUTOLOGO DI CELLULE EMATOPOIETICHE IN PAZIENTI AFFETTI DA MIELOMA MULTIPLO CHE NON HANNO RISPOSTO A PRECEDENTI TERAPIE AD ALTE DOSI.

Ongoing
2
73
Europe
Levact ® i.v., Not applicable, Powder and solution for solution for injection, Levact®
FONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus), Mundipharma
Multiple myeloma Mieloma multiplo, Patients with multiple myeloma Pazienti con mieloma multiplo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01661881: Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Checkmark Mantle cell lymphoma
Jan 2016 - Jan 2016: Mantle cell lymphoma
Active, not recruiting
2
23
US
Rituximab, Rituxan, Bendamustine, Treanda, Cytarabine, Depocyt
Dana-Farber Cancer Institute, Massachusetts General Hospital
Mantle Cell Lymphoma
02/15
03/25
2008-005687-13: Estudio Fase II abierto prospectivo no aleatorizado para valorar la combinación de rituximab, bendamustina, mitoxantrone, dexametasona (R-BMD) en pacientes con Linfoma Folicular refractarios o en recaída

Ongoing
2
60
Europe
Bendamustina, RIBOMUSTIN
GELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea)
Linfoma Folicular refractarios o en recaída
 
 
2010-021451-12: Bendamustine, thalidomide and dexamethasone in relapsed/refractory myeloma

Ongoing
2
98
Europe
Bendamustine, Thalidomide, Dexamethasone, Levact, Celgene Thalidomide, Dexamethasone, Levact, Celgene Thalidomide, Dexamethasone
University of Leeds
Relpsed or refractory multiple myeloma
 
 
2010-020072-33: Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma

Ongoing
2
70
Europe
RIBOMUSTIN, VELCADE, DESAMETASONE FOSF*IM EV 1F 8MG, SOLDESAM FTE, RIBOMUSTIN, VELCADE, DESAMETASONE FOSF*IM EV 1F 8MG, SOLDESAM FTE
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
Relapsed or refractory multiple myeloma
 
 
2008-007125-39: A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation

Ongoing
2
12
Europe
Lenalidomide, Bendamustine, CC-5013, Revlimid, Revlimid
Klinik f. Innere Med., Fachabteilung Hämatologie
AL-amyloidose
 
 
2011-000293-62: Phase II, Open, National, Multicenter Study of Bendamustine, Bortezomib (Velcade) and prednisone (BVP) in patients with newly diagnosed multiple myeloma (BenVelPres) Estudio de Fase II Abierto, Nacional, Multicéntrico de Bendamustina, Bortezomib (Velcade) y Prednisona (BVP) en Pacientes con Mieloma Múltiple de Nuevo Diagnóstico (BenVelPres)

Ongoing
2
60
Europe
Velcade, LEVACT, PREDNISONA, Velcade, LEVACT, VELCADE 3,5 mg, polvo para solución inyectable, LEVACT 2,5 mg/ml polvo para concentrado para solución para perfusión, VELCADE 3,5 mg, polvo para solución inyectable, LEVACT 2,5 mg/ml polvo para concentrado para solución para perfusión
Fundación PETHEMA, Fundación PETHEMA
MULTIPLE MYELOMA MIELOMA MÚLTIPLE
 
 
2010-018866-21: Intensified program including Bendamustine followed by PBSC mobilization and high dose therapy and autograft for patients with relapsed or resistant CD 20+ Follicular Non Hodgkin Lymphoma: a multicenter, pivotal GITIL study

Ongoing
2
20
Europe
Bendamustine Hydrochloride, ELOXATIN*IV FL POLV 100MG, Bendamustine Hydrochloride, ELOXATIN*IV FL POLV 100MG
A.I.L. (ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE, LINFOMI E MIELOMI
RESISTANT FOLLICULAR NON HODGKIN LYNPHOMA
 
 
NCT02401503 / 2014-000580-40: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Checkmark In combination with obinutuzumab following bendamustine
Aug 2018 - Aug 2018: In combination with obinutuzumab following bendamustine
Active, not recruiting
2
66
Europe
Bendamustine, GA101, Obinutuzumab, ABT-199, Venetoclax, GDC-0199
German CLL Study Group, Hoffmann-La Roche, AbbVie
Chronic Lymphocytic Leucemia
12/16
12/24
NCT01286272: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Active, not recruiting
2
135
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP-18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Positron Emission Tomography with Radiolabeled Targeting Agent, Positron Emission Tomography with Radiolabeled Targeting Agents
National Cancer Institute (NCI)
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
05/17
03/25
2017-004628-31: Venetoclax after chemotherapy R-BAC in high-risk elderly patients with mantle cell lymphoma Venetoclax dopo chemioterapia R-BAC in pazienti anziani affetti da linfoma mantellare

Not yet recruiting
2
130
Europe
Venclyxto, Film-coated tablet, Venclyxto
Fondazione Italiana Linfomi ONLUS, AbbVie S.r.l.
Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
PTL, NCT02753062: Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

Recruiting
2
22
RoW
bendamustine, rituximab, symbenda, mabthera
Asan Medical Center, Cheolwon Suh
Diffuse Large B Cell Lymphoma
08/18
08/23
NCT03623373: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Active, not recruiting
2
13
US
Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Acalabrutinib, Calquence®, Cytarabine, Cytosar-U, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
Washington University School of Medicine, Acerta Pharma BV
Mantle Cell Lymphoma
02/20
02/25
2012-003947-31: OPTIMAL: Optimising Renal Outcome in Myeloma renal failure

Not yet recruiting
2
120
Europe
Thalidomide celgene, Velcade, Levact, J9041, Capsule, hard, Injection, Infusion, Thalidomide Celgene™, Velcade, Levact
Oxford University Hospitals NHS Trust, Janssen-Cilag, NAPP Pharmaceuticals
Myeloma and renal impairment, Cancer of bone marrow, kidney disfunction, Diseases [C] - Cancer [C04]
 
 
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia

Not yet recruiting
2
40
Europe
Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax)
Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG
Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04]
 
 
CLL2-BAAG, NCT03787264 / 2017-003133-28: Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

Completed
2
46
Europe
Bendamustine, Obinutuzumab, GA101, Gazyvaro, Acalabrutinib, ACP-196, Calquence, Venetoclax, ABT-199, Venclyxto
German CLL Study Group
Chronic Lymphoid Leukemia
02/21
09/23
PrE0403, NCT03113422: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Completed
2
56
US
Induction Venetoclax, GDC-0199, ABT-199, RO5537382, Maintenance Venetoclax
PrECOG, LLC., Genentech, Inc.
Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
05/21
01/23
2019-002499-14: RELYAGE (Relapse LYmphoma AGEd) : Assessment of survival and autonomy with Rituximab-Lenalidomide and Rituximab-Chemotherapy for elderly patients with relapsed diffuse large-B cell lymphoma : a randomized phase II RELYAGE (RELAPSE LYMPHOMA AGED): ETUDE DE PHASE II RANDOMISEE EVALUANT LA SURVIE AVEC PRESERVATION DE L’AUTONOMIE DE RITUXIMAB PLUS CHIMIOTHERAPIE OU RITUXIMAB PLUS LENALIDOMIDE CHEZ DES PATIENTS AGES EN RECHUTE D’UN LYMPHOME DIFFUS A GRANDES CELLULES B

Not yet recruiting
2
114
Europe
rituximab, Capsule, hard, Powder for solution for infusion, Solution for infusion, revlimid, gemcitabine, oxaliplatine, bendamustine, Mabthera
CHU Amiens-Picardie, DGOS
diffuse large B cell lymphoma lymphome diffus à grandes cellules, lymphoma lymphome, Diseases [C] - Cancer [C04]
 
 
FIL_V-RBAC, NCT03567876: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Active, not recruiting
2
141
Europe
Venetoclax, Venclyxto (commercial name)
Fondazione Italiana Linfomi - ETS, AbbVie
Lymphoma, Mantle-Cell
07/21
07/25
2021-000468-32: Study for patients with mantle cell lymphoma (one type of lymphomas = lymph node cancer), aimed to answer the question if patients who relapse after previous therapy with Bruton tyrosine kinase inhibitor (type of biologivcal treatment) will be beneficiary adding of polatuzumab vedotin (new type of biological treatment) to commonly used treatment with bendamustine and rituxima (combination of chemotherpay and biological treatment) Studie pro pacienty s lymfomem z plášťových buněk (jeden z podtypů lymfomu), která se snaží odpovědět na otázku, zda u pacientů, u kterých selhala předchozí léčba inhibitory Brutonovy kinázy (typ biologické léčby), bude přinosem přidání polatuzumab vedotinu (nový typ biologické léčby) k již běžně používané záchranné léčbě (kombinace bendamustinu a rituximabu (tj. chemoterapie a biologické léčby)

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Bendamustine Accord 25 mg/ml, Mabthera, RO5541077, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustine Accord, Mabthera
Kooperativní lymfomová skupina, z.s., Kooperativní lymfomová skupina, z.s.
Mantle cell lymphoma lymfom z plášťových buněk, aggressive lymph node cancer of B-cell origin agresivní nádorové onemocnění z mízních uzlin z B-buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
GABe2016, NCT03492775 / 2016-000755-27: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed
2
46
Europe
Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin
Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG
Indolent Non-hodgkin Lymphoma
11/21
12/22
2021-002630-17: Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine andDexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patientsHodgkin resistant to treatment of 1 line.

Not yet recruiting
2
84
Europe
Nivolumab, Concentrate for solution for infusion, OPDIVO
Medical Unicersity of Gdansk, Medical Research Agency
Refractory / relapsed Hodgkin's lymphoma Oporny/nawrotowy chłoniak Hodgkina, Refractory / relapsed Hodgkin's lymphoma, Diseases [C] - Cancer [C04]
 
 
CLL2-BCG, NCT02445131 / 2014-000582-47: Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL

Completed
2
48
Europe
Bendamustine, GA101, Obinutuzumab, CAL-101, Idelalisib
German CLL Study Group, Hoffmann-La Roche, Gilead Sciences
Chronic Lymphocytic Leucemia
03/22
03/22
2021-006030-40: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA

Not yet recruiting
2
16
Europe
Powder for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustin Accord, MabThera
Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
MANTLE CELL LYMPHOMA, MANTLE CELL LYMPHOMA, Diseases [C] - Cancer [C04]
 
 
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Active, not recruiting
2
33
US
Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan
PrECOG, LLC., Genentech, Inc.
Mantle Cell Lymphoma
10/22
11/24
NCT01059786: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Checkmark P2 data in HCL
Nov 2011 - Nov 2011: P2 data in HCL
Active, not recruiting
2
69
US
Pentostatin, Nipent, Rituximab, Rituxan, Bendamustine, Bendeka, Treanda, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Epinephrine, Adrenaline, Antihistamines, Corticosteroids, Corticoid, Bronchodilators, Broncholytic, Intravenous (IV) Saline
National Cancer Institute (NCI)
Hairy Cell Leukemia
12/22
12/25
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms.

Not yet recruiting
2
150
Europe
Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV
Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04]
 
 
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark ASH 2013
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
08/24
08/24
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
23
US
Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382
Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
09/24
04/26
NCT01437709: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Completed
2
30
US
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
09/23
09/23
BURGUND, NCT03615664: The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

Active, not recruiting
2
115
Europe
Bendamustine, Treanda, Gemcitabine, Gemzar, Dexamethasone, PET/CT, Autologous Stem Cell Transplant, ASCT
Polish Lymphoma Research Group
Hodgkin's Lymphoma
06/24
09/24
NCT04217317: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Recruiting
2
12
US
CPI 613, devimistat, Bendamustine, Bendeka, Treanda, Bendamustine Hydrochloride
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma
11/24
06/25
NCT06136351: A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Recruiting
2
23
RoW
Zanubrutinib, Rituximab, Bendamustin
Ruijin Hospital
Lymphoma, Mantle-Cell
11/27
11/27
NCT06415708: Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Recruiting
2
134
RoW
Obinutuzumab Combined With Bendamustine
Institute of Hematology & Blood Diseases Hospital, China
B Cell Lymphoma
11/24
06/26
NCT03609593: Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Active, not recruiting
2
42
US
Bendamustine, Treanda, Venetoclax, ABT-199, Venclexta, Rituximab, Rituxan
Nicole Lamanna
Chronic Lymphocytic Leukemia
01/25
12/25
NCT04587687: Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recruiting
2
23
US
Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35
Joseph Tuscano, National Cancer Institute (NCI), Seagen Inc.
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
05/25
ECOG-ACRIN E1411, NCT01415752: Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
373
Canada, US
rituximab, bendamustine hydrochloride, bortezomib, lenalidomide
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Lymphoma, Neurotoxicity, Therapy-related Toxicity
12/24
09/31
PTBCy, NCT04943757: Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

Recruiting
2
50
RoW
Bendamustine Hydrochloride, Cyclophosphamid
St. Petersburg State Pavlov Medical University
Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
12/23
12/24
FluBuBe, NCT04942730: Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation

Completed
2
50
RoW
Fludarabine, Bendamustine Hydrochloride, Busulfan, Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus 5Mg Cap
St. Petersburg State Pavlov Medical University
Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
04/24
04/24
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
CheckMate 744, NCT02927769 / 2016-002347-41: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Hourglass Feb 2021 - Dec 2021 : From CheckMate 744 trial for r/r classic hodgkin lymphoma
Checkmark FRom CheckMate 744 trial at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: FRom CheckMate 744 trial at ASH 2018 [screenshot]
Active, not recruiting
2
72
Europe, Canada, US, RoW
Nivolumab, BMS-936558, Opdivo, brentuximab vedotin, bendamustine
Bristol-Myers Squibb, Seagen Inc.
Hodgkin Disease
06/24
11/24
Prolgo-HL, NCT05757466: Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

Recruiting
2
30
RoW
Prolgolimab, Combination with prolgolimab and bendamustine
St. Petersburg State Pavlov Medical University, N.N. Petrov National Medical Research Center of Oncology
Hodgkin Lymphoma
03/24
03/25
NCT06477549: BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Recruiting
2
220
RoW
Bendamustine Hydrochloride, Ruxolitinib
St. Petersburg State Pavlov Medical University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
06/28
06/29
ZFCR/ZBR, NCT05287984: Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

Not yet recruiting
2
63
RoW
Zanubrutinib, Fludarabine, cyclophosphamide and rituximab, ZFCR regimen, Zanubrutinib, bendamustine, rituximab, ZBR regimen
Institute of Hematology & Blood Diseases Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
06/24
11/24
GOLSEEK-2, NCT06425302: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Not yet recruiting
2
90
Europe, Canada, US, RoW
Golcadomide, CC-99282, BMS-986369, Rituximab, Mabthera, Cyclophosphamide, Endoxan, Doxorubicin, Caelyx, pegylated liposomal doxorubicin, PLD, Vincristine, Prednisone, Bendamustine
Celgene
Lymphoma, Follicular
11/26
11/28
BRAWM, NCT04624906: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Active, not recruiting
2
59
Canada
Acalabrutinib, Calquence, Bendamustine, Treanda, Rituximab, Rituxan
Sunnybrook Health Sciences Centre, AstraZeneca
Waldenstrom Macroglobulinemia
12/24
03/30
NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting
2
360
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Liver Lymphoma, Mantle Cell Lymphoma
12/24
03/25
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
110
US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
12/24
12/26
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
56
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
02/25
02/27
NCT05660993: Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
50
RoW
Nivolumab
National Research Center for Hematology, Russia
Hodgkin Lymphoma
03/25
03/25
ZBR, NCT05914662: Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM

Recruiting
2
30
RoW
Zanubrutinib, Bendamustine and Rituximab
Institute of Hematology & Blood Diseases Hospital
Waldenstrom Macroglobulinemia
03/25
12/25
NCT03856216: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Recruiting
2
44
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Bendamustine, SDX-105, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
03/25
03/25
CLL2-BZAG, NCT04515238: Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Active, not recruiting
2
42
Europe
Bendamustine, Treanda, Bendeka, Obinutuzumab, GA101, Gazyvaro, Zanubrutinib, BGB-3111, Venetoclax, ABT-199, Venclyxto
German CLL Study Group
Chronic Lymphoid Leukemia
04/25
03/27
CZ-WM01, NCT05979948: A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

Recruiting
2
60
RoW
Zanubrutinib, Bendamustine, Rituximab
Shanghai Changzheng Hospital, RenJi Hospital, Huashan Hospital, Shanghai 6th People's Hospital, Huadong Hospital
Waldenström's Macroglobulinemia
04/25
12/25
FLMRD, NCT04934930: Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Recruiting
2
40
RoW
Bendamustin, Ribomustin, Obinutuzumab, Gazyva
Meir Medical Center, Rabin Medical Center, Tel-Aviv Sourasky Medical Center, Assuta Ashdod Hospital, Ziv Medical Center
Follicular Lymphoma
08/25
08/25
NCT05025423: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Recruiting
2
40
US
Venetoclax Oral Tablet [Venclexta], rituximab infusion [Rituxan], Bendamustine infusion
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AbbVie
Mantle Cell Lymphoma
09/25
09/26
ChiCTR2100047272: Chidamide or Zanubrutinib combined withPrednisone, Etoposide, and Lenalidomide as introductive treatment following CD20 antibody and Bendamustine as consolidated therapy for Relapsed or Refractory indolent B-cell non Hodgkin Lymphoma

Recruiting
2
50
 
Bendamustine combined with rituximab
The Hospital Affiliated of Qingdao University; The Hospital Affiliated of Qingdao University, The Hospital Affiliated of Qingdao University
indolent non Hodgkin B-cell Lymphoma
 
 
ChiCTR2100046858: PD-1 Antibody combined with Chidamide, Prednisone, Etoposide, and Lenalidomide as introductive treatment following PD-1 antibody combine with Pemetrexed and Pegaspargase/Bendamustine as consolidated therapy for Relapsed or Refractory Peripheral T-cell Lymphoma.

Recruiting
2
60
 
PD-1 Antibody combined with Chidamide, Prednisone, Etoposide, and Lenalidomide as introductive treatment following Pegaspargase and Pemetrexed as consolidated therapy.
The Affiliated Hospital of Qingdao University; The Hospital Affiliated of Qingdao University, The Hospital Affiliated of Qingdao University
Peripheral T-cell Lymphoma
 
 
ChiCTR2100046855: CD20 Antibody combined with Chidamide, Prednisone, Etoposide, and Lenalidomide as introduction treatment following CD20 antibody and Bendamustine as consolidated therapy for Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
135
 
Nil
The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, The Affiliated Hospital of Qingdao University
Refractory Diffuse Large B-cell Lymphoma
 
 
ChiCTR2200057539: A prospective, multicenter, one-arm, open trial of cedarbenamine in combination with prednisone, etoposide, and lenalidomide induced bendamustine in combination with CD20 monoclonal antibody consolidation in elderly/frail relapsed/refractory follicular lymphoma (FL)

Not yet recruiting
2
66
 
Chidamide, bendamustine, Lenalidomide, etoposide, prednisone +CD20 monoclonal antibody
The Hospital Affiliated of Qingdao University; The Hospital Affiliated of Qingdao University, The Hospital Affiliated of Qingdao University
Follicular lymphoma
 
 
KEsTREL-01, NCT04510636: Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Recruiting
2
37
Canada
Pembrolizumab, KEYTRUDA, Bendamustine Hydrochloride, TREANDA
University Health Network, Toronto
Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
06/26
06/26
CLSGMCLPOLA, NCT04913103: Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Polivy, Bendamustine Hydrochloride, Bendamustine Accord, Bendamustine Glenmark, Bendamustine KABI, Rituximab, Mabthera, Rixathon, Truxima
Czech Lymphoma Study Group
Lymphoma, Mantle-Cell
08/26
08/27
NCT03755804: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Recruiting
2
250
US
bendamustine, TREANDA (R), Etoposide, VP-16, Vepeside, Doxorubicin, Adriamycin (R), Bleomycin, Blenoxane (R), Vincristine, Oncovin (R), Vinblastine, Velban (R), Prednisone, Prednisolone, Filgrastim, Neupogen (R), Brentuximab Vedotin, Adcetris, Cyclophosphamide, Cytoxan (R), DTIC, DACARBAZINE (R), Dimethyl Triazeno Imidazole Carboximide, Quality of Life Measurements, Quality of Life Measurements (QOL), Radiotherapy, radiation therapy, irradiation
St. Jude Children's Research Hospital, Teva Pharmaceuticals USA, Seagen Inc.
Hodgkin Lymphoma
01/27
07/28
NCT05868395: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Recruiting
2
16
Europe
Polatuzumab, bendamustin und rituximab, Polivy, Bendamustin, Mabthera
Medical University of Vienna
Mantle-cell Lymphoma
05/27
05/27
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
NCT05245656: A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

Recruiting
2
90
RoW
RB/RBAC alternating, RB
Kim, Seok Jin
Mantle Cell Lymphoma
12/29
12/29
2011-000097-56: A randomised phase I/II trial of lenalidomide and rituximab with or withoutbendamustine in patients ≥ 18 years with relapsed follicular lymphoma

Ongoing
1/2
168
Europe, RoW
Lenalidomide (Revlimid 5 mg), Lenalidomide (Revlimid 10 mg), Lenalidomide (Revlimid 15 mg), Rituximab, Bendamustine hydrochloride 25mg (Levact), Bendamustine hydrochloride 100mg (Levact), EU/1/07/391/001, Capsule, hard, Concentrate and solvent for solution for infusion, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Revlimid 5 mg capsules, Revlimid 10 mg capsules, Revlimid 15 mg hard capsules, Mabthera, Levact
HOVON Foundation, KWF, Celgene, Mundipharma, Cancer Research UK grant (CTAAC), HOVON Foundation
Follicular lymphoma., Cancer in the lymph nodes., Diseases [C] - Cancer [C04]
 
 
NCT02056756: Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Completed
1/2
63
Europe
Carfilzomib, Krypolis
Stichting European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
09/15
01/23
2008-007246-60: Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma

Ongoing
1/2
40
Europe
Revlimid, Revlimid, Mabthera, Ribomustin, Revlimid, Mabthera, Ribomustin
Nordic Lymphoma Group
Mantle cell lymphoma
 
 
BendAlem, 2008-004987-37`ACTRN12610000060044: Bendamustine Combined with Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) – A Phase I/II Trial with Concomitant Evaluation of Safety and Efficacy

Completed
1/2
20
Europe
Bendamustin, Ribomustin, Ribomustin
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH, Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Chronic Lymphocytic Leukaemia (CLL)
 
08/12
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Active, not recruiting
1/2
56
US
Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone
Cristina Gasparetto, Celgene
Multiple Myeloma
12/16
01/25
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02678299 / 2015-000758-39: Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Active, not recruiting
1/2
60
Europe
PREBEN
University of Aarhus
Malignant Lymphoma
02/22
12/25
NCT04762745: The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1/2
56
RoW
Pomalidomide, Pomalidomide( Anyue®, Chia Tai TIANQING, China), Bendamustine, Bendamustine( Leweixin®, Chia Tai TIANQING, China), Dexamethasone
Sun Yat-sen University
Relapsed, Refractory, Multiple Myeloma
02/22
02/23
2020-002927-13: Atezolizumab treatment together with the BEGEV regimen in patients with resistant Hodgkin's lymphoma and candidates for autologous stem cell transplantation. Trattamento di atezolizumab associato a combinazione BEGEV in pazienti con linfoma di Hodgkin resistente e candidati al trapianto autologo di cellule staminali.

Not yet recruiting
1/2
140
Europe
Atezolizumab, Bendamustina, Gemcitabina, Vinorelbina, [IMP2], [IMP3], [IMP4], [IMP5], [IMP6], [IMP1], Concentrate for solution for infusion, Powder for concentrate for solution for infusion, TECENTRIQ - 840 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 40 ML, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 10 ML, Gemcitabina cloridrato, VINORELBINA ACTAVIS - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche S.p.A.
Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04897477: Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

Recruiting
1/2
30
RoW
Azacytidine, Bendamustine and Piamprizumab
Chinese PLA General Hospital
Non-hodgkin Lymphoma,B Cell
04/22
04/23
ChiCTR2200055163: A Phase Ib Study of TQ-B3525，a PI3K-α and -δ inhibitor, in Combination with Rituximab and Bendamustine in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
30
 
TQ-B3525 in combination with rituximab and bendamustine
Sichuan Cancer Hospital; Sichuan Cancer Hospital, CHIATAI TIANQING
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
 
 
2022-001040-23: Treatment of relapsed or refractory B-cell lymphoma with CAR-T therapy produced by a new technology. Tratamiento del linfoma de células B en recaída o refractario con terapia CAR-T producida por una nueva tecnología.

Not yet recruiting
1/2
27
Europe
TranspoCART19, Cyclophosphamide, Fludarabina, Bendamustina, Tocilizumab, Cetuximab, Injection/infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, , Genoxal 25mg/ml, Fludarabina Teva 25 mg/ml, Bendamustina Tillomed 2,5 mg/ml, RoActemra 20 mg/m, Erbitux 5 mg/ml
Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL, Instituto de Salud Carlos III
Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Diseases [C] - Cancer [C04]
 
 
NCI-2012-02072, NCT01664910: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Completed
1/2
27
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
06/23
06/23
NCT03739619: Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, not recruiting
1/2
54
US
Bendamustine, Bendamustine Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Emory University, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
12/24
12/24
NCT05551936: A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Recruiting
1/2
42
US
Bendamustine, Bendeka, Treanda, Rituximab, Rituxan, Tazemetostat, Tazverik
Vaishalee Kenkre, Epizyme, Inc., University of Wisconsin, Madison
Follicular Lymphoma
08/24
05/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT04022239: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting
1/2
25
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Bendamustine, SDX-105, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, CellCept, MMF, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid System Neoplasm
07/25
07/25
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
108
US
AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
Artiva Biotherapeutics, Inc.
Non Hodgkin Lymphoma
11/24
11/24
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
140
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
05/25
12/28
NCT05451771: Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Recruiting
1/2
53
US
Venetoclax Oral Tablet, 200 mg, Venclexta, FISH assay, t(11;14) FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Decadron, Hemady, Dexamethasone Oral, 20 mg, Daratumumab Injection, Darzalex, Bendamustine, Treanda, Pomalidomide, Pomalyst, Ixazomib, Ninlaro, Venetoclax MTD with Dexamethasone
Rajshekhar Chakraborty, MD, Genentech, Inc.
AL Amyloidosis
09/26
09/26
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29

Download Options